Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On 8 March 2025, the Multiple Sclerosis Clinical Trials Unit hosted 92 patients and family members/carers at the Unipart Conference Centre in Oxford.

The day was dedicated in the honour of Dr Matthew Craner who has sadly passed away in February 2024. We wanted to recognize and celebrate his contribution and achievements to commemorate the impact he made on MS research, education and service improvement. We marked the date for Patient Day on 8 March 2025, International Women’s Day, to acknowledge contributions of women in MS research.

The main aim of the day was to showcase the high quality of research that is being undertaken in Oxford, both commercially funded and investigator-led and impacts on the care of people affected by MS and their carers.

Several researchers then presented the projects they are currently working in the field of MS alongside Keynote Address in memory of Dr Matthew Craner.

We celebrated the International Women’s Day in the afternoon by reviewing Women’s role within MS research over the past decades. The journey of the Multiple Sclerosis Trials Unit was showcased from perception to date alongside the ‘Upskilling’ research nurses on Expanded Disability Scoring Scale training.

 

“I really enjoyed hearing about the variety of research happening in this area and in Oxford. It's really encouraging to hear about all the work happening, how our samples are being used and all the collaboration both in and outside Oxford. Love these sessions. Great level too as I appreciate the way the speakers breakdown their presentations so people like me could follow along." 

“It was a very informative day, you all did so well, extremely welcoming & the refreshments & lunch were delicious."  - Patient attendees

Similar stories

Oxford researchers uncover how Parkinson's disease protein damages brain cells

A new study reveals a key mechanism by which the protein alpha-synuclein, the hallmark of Parkinson's disease, damages neurons (brain cells) by blocking a vital cellular gateway. The results of the study, published in Nature Communications, help to explain how the disease begins and highlights a potential new target for treatment.

New Lancet review calls for urgent action to tackle the growing global threat of encephalitis

The review highlights encephalitis as an urgent global health challenge and calling for faster diagnosis, improved treatments, and strengthened prevention strategies to reduce death and disability worldwide.

Two researchers from NDCN join global network to unravel the complexity of Parkinson’s disease

Two scientists from NDCN, Professor Andrew Sharott (Team leader) and Professor Laura Parkkinen (Co-Investigator) have been selected for multi-year grants to join the Collaborative Research Network (CRN) an international, multidisciplinary, multi-institutional network working to address high-priority research questions about Parkinson's disease.

Study shows that non-invasive ultrasound shows promise for treating Parkinson’s disease

Oxford researchers have shown for the first time that ultrasound could have similar effects on brain activity in Parkinson’s sufferers as implanted deep brain stimulation (DBS) electrodes. This opens the door to new treatment approaches that could avoid surgery.

Collaboration with the Nepal Public Health Foundation (NPHF) explores maternal health and epilepsy

A new study, co-led by Professor Arjune Sen and supported by Nuffield Department of Clinical Neurosciences, aims to improve understanding of the risk factors, care pathways and broader health and social impacts of epilepsy in Nepal.

New funding boosts Oxford research into inflammatory neuropathies

To mark Rare Disease Day on 28 February, we’re highlighting the research of Professor Simon Rinaldi and Dr Nicolas Dubuisson, and celebrating a major new $600,000 grant to progress their fight against inflammatory neuropathies.